Samsung Biologics statement regarding change in CEO stock ownership
Dr. Tae Han Kim, President and CEO of Samsung Biologics, acquired an additional 15,000 shares of the company in the open market during the course of four days on April 5th, 6th, 7th, and 10th. The shares were purchased at an average price of KRW 177,729 per share, at a total purchase price of approximately KRW 2,665,927,500.
Dr. Kim, as an inside director, could not participate in the company’s employee stock ownership plan last year, and therefore purchased 20,000 shares, worth approximately KRW 2.8 billion, in the open market during the course of two days on November 10th and 11th, right after the company’s IPO.
By acquiring an additional 15,000 shares this April, Dr. Kim now owns a total of 35,000 shares, approximately 0.05% of the company’s stock.
Samsung Biologics statement regarding change in CEO stock ownership
Dr. Tae Han Kim, President and CEO of Samsung Biologics, acquired an additional 15,000 shares of the company in the open market during the course of four days on April 5th, 6th, 7th, and 10th. The shares were purchased at an average price of KRW 177,729 per share, at a total purchase price of approximately KRW 2,665,927,500.
Dr. Kim, as an inside director, could not participate in the company’s employee stock ownership plan last year, and therefore purchased 20,000 shares, worth approximately KRW 2.8 billion, in the open market during the course of two days on November 10th and 11th, right after the company’s IPO.
By acquiring an additional 15,000 shares this April, Dr. Kim now owns a total of 35,000 shares, approximately 0.05% of the company’s stock.
Share article
Related Content